MedTrace Logo

Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (Z-AMD)

NCT04304755 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-04-05

No results posted yet for this study

Summary

A pilot study of zoledronic acid as adjuvant therapy to standard anti-vascular endothelial growth factor (anti-VEGF) treatment for neovascular age-related macular degeneration (AMD).

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

DRUG

Zoledronic Acid 5 MG in 5 ML Injection

Zoledronic acid

DRUG

Placebos

NaCl 0.9%

Sponsors & Collaborators

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Morten C Moe, MD, PhD · Oslo University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-25
Primary Completion
2024-01-24
Completion
2024-01-24

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04304755 on ClinicalTrials.gov